WallachBeth Capital Announces Closing of Tenon Medical, Inc. $4.2 Million Public Offering

Rhea-AI Summary

Tenon Medical (NASDAQ:TNON) closed a public offering totaling $4.2 million in gross proceeds. The deal included 11,052,631 common shares (or pre-funded warrants) plus common warrants for up to 13,263,159 shares at a combined price of $0.38 per share and warrant.

Proceeds are earmarked for partial repayment of convertible notes, commercial expansion, clinical research, R&D and product launches, inventory and instrumentation, marketing, working capital and general corporate purposes.

Positive

• Gross proceeds of $4.2 million strengthen liquidity
• Issuance of 11,052,631 shares and warrants broadens capital base
• Proceeds allocated to partial repayment of outstanding convertible notes
• Funding supports commercial expansion, including new sales reps and distributors
• Capital designated for clinical studies to support reimbursement and coverage
• Resources directed to R&D and future product launches

Negative

• New issue of 11,052,631 shares plus up to 13,263,159 warrant shares may dilute existing shareholders
• Portion of proceeds used for debt repayment rather than solely for growth initiatives
• Common warrant coverage may expand to 16,578,949 shares if a reverse stock split occurs

News Market Reaction – TNON

-0.09% 3.8x vol

31 alerts

-0.09% Session close to close

+53.7% Peak Tracked

-14.1% Trough Tracked

$3.86M Market Cap

3.8x Rel. Volume

In the Jul 1 session, TNON declined 0.09%, reflecting a mild negative market reaction. Argus tracked a peak move of +53.7% during that session. Argus tracked a trough of -14.1% from its starting point during tracking. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.8x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms closing of a $4.2 million equity-and-warrant financing intended for debt ...

Analysis

This announcement confirms closing of a $4.2 million equity-and-warrant financing intended for debt repayment and commercial expansion. Prior offerings have triggered large price swings, so ongoing financing needs and warrant overhang remain key risks to monitor against execution milestones.

Key Figures

Gross proceeds: $4.2 million Shares offered: 11,052,631 shares Common warrants: 13,263,159 warrants +4 more

7 metrics

Gross proceeds $4.2 million Aggregate gross proceeds of the public offering

Shares offered 11,052,631 shares Common stock (or pre-funded warrants) in the offering

Common warrants 13,263,159 warrants Common stock purchase warrants issued with the shares

Warrants post-split 16,578,949 shares Common stock underlying warrants if reverse split occurs

Offering price $0.38 per share Combined price per share (or pre-funded warrant) and warrant

Warrant exercise price $0.38 per share Exercise price of the Common Warrants

Pre-funded exercise $0.001 per share Exercise price of each pre-funded warrant

Previous Offering Reports

4 past events · Latest: Jun 30 (Negative)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 30	Offering pricing	Negative	-26.9%	Pricing of $4.2M equity and warrant financing at $0.38 per unit.
Jun 30	Offering pricing	Negative	-26.9%	Company announcement of $4.2M public offering structure and uses.
Sep 17	Offering closing	Negative	-18.9%	Closing of $4.5M at-the-market public offering with warrants.
Sep 12	Offering pricing	Negative	+71.6%	Pricing of $4.5M at-the-market offering with five-year warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Offering-related announcements have typically produced sharp, often negative moves, with one standout positive spike in 2024.

Key Terms

pre-funded warrants, common warrants, reverse stock split, registration statement on form s-1

4 terms

pre-funded warrants financial

"or pre-funded warrants in lieu thereof), together with common stock purchase warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

common warrants financial

"shares of common stock (the "Common Warrants"), at a combined public offering price"

A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.

reverse stock split financial

"will be increased to 16,578,949 if the Company effects a reverse stock split."

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

registration statement on form s-1 regulatory

"pursuant to a registration statement on Form S-1 (File No.: 333-296952), as amended"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JERSEY CITY, N.J., July 1, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ: TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company.

The offering consisted of 11,052,631 shares of our common stock, par value $0.001 per share (or pre-funded warrants in lieu thereof), together with common stock purchase warrants to purchase up to 13,263,159 shares of common stock (the "Common Warrants"), at a combined public offering price of $0.38 per share of common stock (inclusive of the pre-funded warrant exercise price of $0.001) and accompanying Common Warrants. The number of shares of Common Stock underlying the Common Warrants will be increased to 16,578,949 if the Company effects a reverse stock split.

The Company expects to use the net proceeds from the offering for partial repayment of outstanding convertible notes, expansion of the commercial footprint of its product portfolio including training clinicians on current procedures, hiring additional direct sales reps, expansion of its external distribution network, continuing clinical research studies to support reimbursement and coverage efforts, funding research and development including upcoming future launches, and increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes.

WallachBeth Capital LLC acted as sole placement agent in connection with the offering. Sichenzia Ross Ference Carmel LLP acted as legal counsel to the Company and Sheppard, Mullin, Richter & Hampton LLP acted as counsel to WallachBeth Capital LLC.

The Common Warrants will be immediately exercisable and will entitle the holder to purchase one share of common stock at an exercise price of $0.38 per share. Each pre-funded warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $0.001 per share and may be exercised at any time until exercised in full. The common stock (or pre-funded warrant in lieu thereof) and Common Warrants can only be purchased together in this offering but will be immediately issued separately.

The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No.: 333-296952), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"), and the registration statement on Form S-1MEF (File No.: 333-297142). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available, from WallachBeth Capital, LLC, via email at cap-mkts@wallachbeth.com, by calling +1 (646) 237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.

About WallachBeth Capital LLC:

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, supporting issuers and investors in achieving their financial goals. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions and ATM's.

Forward-Looking Statements

This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov statements contain, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-tenon-medical-inc-4-2-million-public-offering-302816085.html

SOURCE WallachBeth Capital LLC

FAQ

What did Tenon Medical (NASDAQ:TNON) announce about its July 2026 public offering?

Tenon Medical announced the closing of a $4.2 million public offering of common stock, pre-funded warrants, and common warrants. According to Tenon, the offering provides capital for debt reduction, commercial expansion, clinical research, R&D, inventory, marketing, working capital, and general corporate purposes.

How many Tenon Medical (TNON) shares and warrants were issued in the July 2026 offering?

The offering included 11,052,631 shares of common stock (or pre-funded warrants) plus common warrants for up to 13,263,159 shares. According to Tenon, warrant coverage could increase to 16,578,949 shares if the company implements a reverse stock split in the future.

What was the public offering price for Tenon Medical (TNON) shares and warrants in July 2026?

Tenon Medical priced the common stock and accompanying warrants at a combined $0.38 per share, inclusive of the $0.001 pre-funded warrant exercise price. According to Tenon, both the common warrants and pre-funded warrants are immediately exercisable following the offering’s closing.

How will Tenon Medical use the $4.2 million raised in its July 2026 TNON offering?

Tenon plans to use net proceeds for partial repayment of convertible notes and broad business expansion. According to Tenon, funds support commercial footprint growth, clinician training, sales hiring, distribution expansion, clinical research, R&D, inventory, instrumentation, marketing, working capital, and corporate needs.

What are the key terms of Tenon Medical’s common and pre-funded warrants from the 2026 TNON offering?

Common warrants are immediately exercisable at $0.38 per share, each for one share of common stock. According to Tenon, pre-funded warrants are exercisable at $0.001 per share, can be exercised at any time, and remain outstanding until fully exercised.

Who acted as placement agent and legal counsel in Tenon Medical’s July 2026 TNON offering?

WallachBeth Capital served as sole placement agent for Tenon Medical’s public offering. According to Tenon, Sichenzia Ross Ference Carmel provided company counsel, while Sheppard Mullin Richter & Hampton represented WallachBeth in connection with the transaction and related documentation.